*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter - as a primary diagnosis code | T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 4.6 | |
| Readmission Rate (%) | 17.8 | |
| Unplanned Readmission Rate (%) | NA | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 918: POISONING AND TOXIC EFFECTS OF DRUGS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 917: POISONING AND TOXIC EFFECTS OF DRUGS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|
| Total Hospitalizations at DRG | 71,748 | |
| Total Hospitalizations with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 79 | |
| DRG Share of Total Hospitalizations | 0.22 | |
| % of Total ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter in DRG | 65.83 | |
| Avg LOS at DRG | 2.93 | |
| Avg LOS with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 2.33 | |
| Readmission Rate at DRG | 33.86 | |
| Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | |
| Unplanned Readmission Rate at DRG | 10.34 | |
| Unplanned Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | |
| Total Medicare payments at DRG | $313,351,773 | |
| Total Medicare payments with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $331,962 | |
| Total Medicare payment per Day at DRG | $1,489 | |
| Total Medicare payment per Day with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $1,804 | |
| Total Medicare payment per Hospitalization at DRG | $4,367 | |
| Total Medicare payment per Hospitalization with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $4,202 | |
| Total Medicare Charges at DRG | $1,750,048,705 | |
| Total Medicare Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $1,381,657 | |
| Avg Charges at DRG | $24,392 | |
| Avg Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $17,489 | |
| Mortality Rate at DRG | 0.22 | |
| Mortality Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | |
| SNF Discharge Rate at DRG | 7.61 | |
| SNF Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | |
| Home Discharge Rate at DRG | 51.88 | |
| Home Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 75.95 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 916: ALLERGIC REACTIONS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 915: ALLERGIC REACTIONS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 312: SYNCOPE AND COLLAPSE | DRG 682: RENAL FAILURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 14,173 | ||||
| Total Hospitalizations with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 4,706 | ||||
| DRG Share of Total Hospitalizations | 0.04 | ||||
| % of Total ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter in DRG | 12.82 | ||||
| Avg LOS at DRG | 1.96 | ||||
| Avg LOS with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 1.86 | ||||
| Readmission Rate at DRG | 10.54 | ||||
| Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 7.83 | ||||
| Unplanned Readmission Rate at DRG | 8.26 | ||||
| Unplanned Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 6.19 | ||||
| Total Medicare payments at DRG | $44,557,195 | ||||
| Total Medicare payments with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $14,727,166 | ||||
| Total Medicare payment per Day at DRG | $1,600 | ||||
| Total Medicare payment per Day with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $1,680 | ||||
| Total Medicare payment per Hospitalization at DRG | $3,144 | ||||
| Total Medicare payment per Hospitalization with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $3,129 | ||||
| Total Medicare Charges at DRG | $278,492,872 | ||||
| Total Medicare Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $89,581,027 | ||||
| Avg Charges at DRG | $19,650 | ||||
| Avg Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $19,035 | ||||
| Mortality Rate at DRG | 0.1 | ||||
| Mortality Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 5.36 | ||||
| SNF Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 5.52 | ||||
| Home Discharge Rate at DRG | 82.28 | ||||
| Home Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 83.11 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 641: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 291: HEART FAILURE AND SHOCK WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 684: RENAL FAILURE WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 292: HEART FAILURE AND SHOCK WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 310,318 | ||||
| Total Hospitalizations with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 1,576 | ||||
| DRG Share of Total Hospitalizations | 0.94 | ||||
| % of Total ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter in DRG | 4.29 | ||||
| Avg LOS at DRG | 3.19 | ||||
| Avg LOS with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 2.53 | ||||
| Readmission Rate at DRG | 20.19 | ||||
| Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 14.68 | ||||
| Unplanned Readmission Rate at DRG | 13.62 | ||||
| Unplanned Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 10.48 | ||||
| Total Medicare payments at DRG | $1,415,392,709 | ||||
| Total Medicare payments with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $6,724,695 | ||||
| Total Medicare payment per Day at DRG | $1,431 | ||||
| Total Medicare payment per Day with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $1,690 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,561 | ||||
| Total Medicare payment per Hospitalization with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $4,267 | ||||
| Total Medicare Charges at DRG | $7,113,640,596 | ||||
| Total Medicare Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $29,904,168 | ||||
| Avg Charges at DRG | $22,924 | ||||
| Avg Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $18,975 | ||||
| Mortality Rate at DRG | 0.63 | ||||
| Mortality Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 19.76 | ||||
| SNF Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 13.45 | ||||
| Home Discharge Rate at DRG | 50.47 | ||||
| Home Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 66.12 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 640: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 208: RESPIRATORY SYSTEM DIAGNOSIS W VENTILATOR SUPPORT <=96 HOURS | DRG 309: CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 189: PULMONARY EDEMA AND RESPIRATORY FAILURE | DRG 470: MAJOR JOINT REPLACEMENT OR REATTACHMENT OF LOWER EXTREMITY WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 231,812 | ||||
| Total Hospitalizations with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 452 | ||||
| DRG Share of Total Hospitalizations | 0.71 | ||||
| % of Total ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter in DRG | 1.23 | ||||
| Avg LOS at DRG | 4.41 | ||||
| Avg LOS with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 4.01 | ||||
| Readmission Rate at DRG | 29.12 | ||||
| Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 23.88 | ||||
| Unplanned Readmission Rate at DRG | 22.82 | ||||
| Unplanned Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 15.6 | ||||
| Total Medicare payments at DRG | $1,743,376,418 | ||||
| Total Medicare payments with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $3,383,012 | ||||
| Total Medicare payment per Day at DRG | $1,704 | ||||
| Total Medicare payment per Day with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $1,868 | ||||
| Total Medicare payment per Hospitalization at DRG | $7,521 | ||||
| Total Medicare payment per Hospitalization with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $7,485 | ||||
| Total Medicare Charges at DRG | $8,543,867,896 | ||||
| Total Medicare Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $15,064,514 | ||||
| Avg Charges at DRG | $36,857 | ||||
| Avg Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $33,329 | ||||
| Mortality Rate at DRG | 2.89 | ||||
| Mortality Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 22.92 | ||||
| SNF Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 22.12 | ||||
| Home Discharge Rate at DRG | 43.02 | ||||
| Home Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 46.68 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 190: CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 280: ACUTE MYOCARDIAL INFARCTION, DISCHARGED ALIVE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 872: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 247: PERCUTANEOUS CARDIOVASCULAR PROCEDURES WITH DRUG-ELUTING STENT WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 392: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 535,322 | ||||
| Total Hospitalizations with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 311 | ||||
| DRG Share of Total Hospitalizations | 1.63 | ||||
| % of Total ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter in DRG | 0.85 | ||||
| Avg LOS at DRG | 4.68 | ||||
| Avg LOS with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 5.07 | ||||
| Readmission Rate at DRG | 23.65 | ||||
| Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 19.33 | ||||
| Unplanned Readmission Rate at DRG | 18.66 | ||||
| Unplanned Readmission Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 16.33 | ||||
| Total Medicare payments at DRG | $3,844,806,408 | ||||
| Total Medicare payments with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $2,222,195 | ||||
| Total Medicare payment per Day at DRG | $1,536 | ||||
| Total Medicare payment per Day with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $1,409 | ||||
| Total Medicare payment per Hospitalization at DRG | $7,182 | ||||
| Total Medicare payment per Hospitalization with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $7,145 | ||||
| Total Medicare Charges at DRG | $19,258,468,078 | ||||
| Total Medicare Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $11,091,621 | ||||
| Avg Charges at DRG | $35,975 | ||||
| Avg Charges with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | $35,664 | ||||
| Mortality Rate at DRG | 1.27 | ||||
| Mortality Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 14.61 | ||||
| SNF Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 15.76 | ||||
| Home Discharge Rate at DRG | 52.12 | ||||
| Home Discharge Rate with ICD T464X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter | 53.7 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| CHRISTIANA CARE WILMINGTON HOSPITAL | 501 W 14TH ST | WILMINGTON | DE | 19801 | 221 |
| RIVERSIDE METHODIST HOSPITAL | 3535 OLENTANGY RIVER RD | COLUMBUS | OH | 43214 | 162 |
| SOUTH SHORE HOSPITAL | 55 FOGG ROAD | SOUTH WEYMOUTH | MA | 02190 | 137 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. ZIAD SOUS | 1145 S UTICA AVE | TULSA | OK | 74104 | 36 |
| Dr. KALYAN AKKINENI | 1001 TOWSON AVE | FORT SMITH | AR | 72901 | 19 |
| Dr. MICHAEL ROBERT KAMMERMAN | 3330 LOMITA BLVD | TORRANCE | CA | 90505 | 16 |